---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-028614"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2026-06-15T12:00:45+00:00"
generated_at: "2026-06-15T12:06:57.935091+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Telomir Pharma publishes preclinical data showing Telomir-Zn reverses insulin resistance in T2DM zebrafish model

## Summary
- Telomir-Zn reduced HOMA-IR from ~10-12 to ~3 after 14 days in diet-induced T2DM zebrafish model.
- Treatment produced dose-dependent improvements in fasting glucose, glucose tolerance, and fasting insulin levels.
- This is the second peer-reviewed publication on Telomir-Zn in 2026, supporting its metal-homeostasis mechanism.
- Telomir-Zn has FDA IND clearance for a Phase 1/2 trial in triple-negative breast cancer (TELO-001).

## SEC filing metadata
- accession: 0001493152-26-028614
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2026-06-15T12:00:45+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315226028614/0001493152-26-028614-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315226028614/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-028614
- JSON: https://secwatch.observer/filing/0001493152-26-028614.json
- Plain text: https://secwatch.observer/filing/0001493152-26-028614.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.